Prs18 the Cost-Effectiveness of Roflumilast in the Management of Severe Copd in the Uk Setting

Abstract

number of published studies on "cost effectiveness" have increased by more than 30%. There is a large variability in CERs for same drugs for different indications, in some cases also varying by biomarkers. Primary care drugs had lower and less variable CERs than specialty drugs. Variations also exist in methodology used by different groups in modeling cost effectiveness, especially for time horizon and comparator. Majority of primary care drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate cost effectiveness. CONCLUSIONS: This analysis shows the range, variability and methods used for calculation of ICER values for these high budget impact drugs and provides lessons for executives and policy makers.

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis

“…The Markov model developed for this analysis was implemented in TreeAge Pro Suite 2009 (TreeAge Software Inc, Williamstown, MA) with a Microsoft ® Office Excel 2003 (Microsoft Corporation, Redmond, WA) front-end and was based on a published COPD model. 14 The relative rate ratios (RRRs) of exacerbation for alternative treatment regimens were calculated based on the results of a recently published mixed treatment comparison (MTC). 15 Using the complete set of RRRs, this analysis was the first to simultaneously compare various treatment regimens commonly used for the management of COPD, via a fully incremental analysis.…”